Table 1.
Identification of Synergy Between PTH and Anticatabolic Drugs
| Therapy | P Value PTH Treatment | P Value Anticatabolic Treatment | P Value PTH × Anticatabolic Interaction |
|---|---|---|---|
| Femur BV/TV | |||
| PTH + ALN [WT] | P < 0.0001 | P = 0.0001 | P = 0.19 |
| PTH + ALN [Nmp4−/−] | P < 0.0001 | P = 0.55 | P = 0.91 |
| PTH + ZOL [WT] | P < 0.0001 | P < 0.0001 | P = 0.02 |
| PTH + ZOL [Nmp4−/−] | P < 0.0001 | P < 0.0001 | P = 0.01 |
| PTH + RAL [WT] | P < 0.0001 | P < 0.0001 | P = 0.0139 |
| PTH + RAL [Nmp4−/−] | P < 0.0001 | P < 0.0001 | P = 0.001 |
| L5 BV/TV | |||
| PTH + ALN [WT] | P < 0.0001 | P = 0.05 | P = 0.31 |
| PTH + ALN [Nmp4−/−] | P < 0.0001 | P = 0.84 | P = 0.38 |
| PTH + ZOL [WT] | P < 0.0001 | P < 0.0001 | P = 0.02 |
| PTH + ZOL [Nmp4−/−] | P < 0.0001 | P < 0.0001 | P < 0.0001 |
| PTH + RAL [WT] | P < 0.0001 | P < 0.0001 | P = 0.0002 |
| PTH + RAL [Nmp4−/−] | P < 0.0001 | P < 0.0001 | P < 0.0001 |
| WB BMD | |||
| PTH + ALN [WT] | P < 0.0001 | P = 0.04 | P = 0.65 |
| PTH + ALN [Nmp4−/−] | P < 0.0001 | P = 0.50 | P = 0.64 |
| PTH + ZOL [WT] | P < 0.0001 | P = 0.0003 | P = 0.8258 |
| PTH + ZOL [Nmp4−/−] | P < 0.0001 | P = 0.0034 | P = 0.3620 |
| PTH + RAL [WT] | P < 0.0001 | P < 0.0001 | P = 0.0007 |
| PTH + RAL [Nmp4−/−] | P < 0.0001 | P < 0.0001 | P = 0.1807 |
| Cortical bone area | |||
| PTH + ALN [WT] | P = 0.0001 | P = 0.0867 | P = 0.9113 |
| PTH + ALN [Nmp4−/−] | P < 0.0001 | P = 0.2717 | P = 0.3244 |
| PTH + ZOL [WT] | P < 0.0001 | P = 0.0663 | P = 0.8497 |
| PTH + ZOL [Nmp4−/−] | P < 0.0001 | P = 0.1095 | P = 0.5698 |
| PTH + RAL [WT] | P < 0.0001 | P = 0.0081 | P = 0.0407 |
| PTH + RAL [Nmp4−/−] | P = 0.0009 | P < 0.0001 | P = 0.1487 |
A series of two-way analyses of variance were used to compare the efficacy of the PTH monotherapy, a specific anticatabolic monotherapy, and the combination of the two drugs. Statistical significance was set at P ≤ 0.05.